Moreover, the preliminary data of an ongoing clinical trial with decitabine with or without bortezomib showed DNMT3A mutations conferred a better response to the hypomethylating agents in AML patients [32]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.